Cardiology
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology
Genetics
Geriatrics/Aging
Hematology/Oncology
Immunology/Allergy
Infectious Disease
Nephrology
Neurology/Neurosurgery
Obstetrics/Gynecology
Pediatrics
Psychiatry
Public Health, Policy, and Training
Pulmonary
Rheumatology
Surgery

Nejm News Une Mise à Jour The New England Journal of Medicine by Specialties

 


The New England Journal of Medicine: Search Results in Endocrinology
The New England Journal of Medicine (NEJM) RSS feed -- Search Results in Endocrinology. NEJM (http://www.nejm.org) is a weekly general medical journal that publishes new medical research findings, review articles, and editorial opinion on a wide variety of topics of importance to biomedical science and clinical practice.

Mechanisms, Pathophysiology, and Management of Obesity
01/01/70 - Seven of the top 10 leading causes of death and disability in the United States today are chronic diseases (e.g. cancer and diabetes). Prevention and treatment of most of these conditions must address the close link with obesity. People who are overweight or obese account for more than two thirds…

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
01/01/70 - Neuroendocrine tumors of the midgut (which is defined as the jejunoileum and the proximal colon) commonly metastasize to the mesentery, peritoneum, and liver and are frequently associated with the carcinoid syndrome. Neuroendocrine tumors of the midgut represent the most common type of malignant…

The Large Pharmaceutical Company Perspective
01/01/70 - Large pharmaceutical companies conduct clinical trials to evaluate efficacy and identify safety issues for candidate drugs as effectively, efficiently, and expeditiously as possible, while addressing simultaneously the requirements of regulatory authorities across the globe. To put the fewest…

Myasthenia Gravis
01/01/70 - Myasthenia gravis is an autoimmune disease in which antibodies bind to acetylcholine receptors or to functionally related molecules in the postsynaptic membrane at the neuromuscular junction. The antibodies induce weakness of skeletal muscles, which is the sole disease manifestation. The weakness…

Breakthroughs for Whom? Global Diabetes Care and Equitable Design
01/01/70 - Ms. L. showed me the empty container of test strips and a box with butterflies on it. They were for a glucometer model I?d never seen before, called a FreeStyle. She explained that the machine had been given to her a few years earlier by a student philanthropic group from Arkansas on a "medical…

Wasting Energy to Treat Obesity
01/01/70 - The concept of enzyme therapy dates back to at least the 19th century, when pancreatic enzymes were offered to patients who had exocrine pancreatic insufficiency. In 1964, Christian de Duve suggested enzyme treatment as a therapeutic strategy for lysosomal disorder: three decades later,…

Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
01/01/70 - Monoclonal antibodies and other therapies that inhibit proprotein convertase subtilisin?kexin type 9 (PCSK9) have been shown to reduce low-density lipoprotein (LDL) cholesterol levels by approximately 50 to 60% in several randomized trials. Whether lowering LDL cholesterol levels by inhibiting…

Nephron Protection in Diabetic Kidney Disease
01/01/70 - The Clinical Implications of Basic Research series has focused on highlighting laboratory research that could lead to advances in clinical therapeutics. However, the path between the laboratory and the bedside runs both ways: clinical observations often pose new questions for laboratory…

Diabetes and Cause-Specific Mortality in Mexico City
01/01/70 - Diabetes is increasingly common in many countries and has been found to increase the risk of death from a wide range of diseases. However, most large studies of diabetes have been conducted in high-income countries where patients have access to good medical care and can receive treatments to…

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
01/01/70 - Cardiovascular disease is the leading cause of death and complications in patients with type 2 diabetes. Recently, trials evaluating a sodium?glucose cotransporter 2 inhibitor (empagliflozin) and a glucagon-like peptide 1 (GLP-1) analogue (liraglutide) have shown improved cardiovascular outcomes in…

Copyright © 2004/2011 Health.Cat

Annuaire de Sante | S'inscrire au MedSante  | Dictionnaire medicale  Forumed des médecins